MX2021011275A - Adyuvantes de vacunas a base de saponina. - Google Patents

Adyuvantes de vacunas a base de saponina.

Info

Publication number
MX2021011275A
MX2021011275A MX2021011275A MX2021011275A MX2021011275A MX 2021011275 A MX2021011275 A MX 2021011275A MX 2021011275 A MX2021011275 A MX 2021011275A MX 2021011275 A MX2021011275 A MX 2021011275A MX 2021011275 A MX2021011275 A MX 2021011275A
Authority
MX
Mexico
Prior art keywords
saponin
prepared
based vaccine
side chain
natural
Prior art date
Application number
MX2021011275A
Other languages
English (en)
Inventor
Pengfei Wang
Original Assignee
Uab Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Res Found filed Critical Uab Res Found
Publication of MX2021011275A publication Critical patent/MX2021011275A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se han preparado varios candidatos a adyuvante de vacuna a base de MS y saponina natural; los derivados de MS se prepararon al incorporar una cadena lateral funcionalizada terminal en la unidad de ácido glucurónico C3 de las saponinas naturales MS I y II a través de la reacción de formación de amida; y los análogos de QS se prepararon mediante síntesis orgánica de múltiples etapas; estas saponinas no naturales mostraron perfiles de actividad inmunoestimulante significativamente diferentes, lo que sugiere que la estructura de la cadena lateral, el núcleo triterpenoide y el dominio de oligosacáridos juntos orquestan la potenciación característica de las respuestas inmunitarias de cada saponina.
MX2021011275A 2019-03-19 2020-03-17 Adyuvantes de vacunas a base de saponina. MX2021011275A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962820477P 2019-03-19 2019-03-19
PCT/US2020/023185 WO2020190959A1 (en) 2019-03-19 2020-03-17 Saponin-based vaccine adjuvants

Publications (1)

Publication Number Publication Date
MX2021011275A true MX2021011275A (es) 2021-12-10

Family

ID=72519135

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011275A MX2021011275A (es) 2019-03-19 2020-03-17 Adyuvantes de vacunas a base de saponina.

Country Status (10)

Country Link
US (1) US20220152196A1 (es)
EP (1) EP3941219A4 (es)
JP (1) JP2022525768A (es)
KR (1) KR20220004970A (es)
CN (1) CN114126419A (es)
AU (1) AU2020241955A1 (es)
BR (1) BR112021018555A2 (es)
CA (1) CA3133985A1 (es)
MX (1) MX2021011275A (es)
WO (1) WO2020190959A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220323578A1 (en) * 2019-06-03 2022-10-13 Pi-Hui Liang Saponin conjugate and vaccine or pharmaceutical composition comprising the same
WO2023225457A1 (en) * 2022-05-18 2023-11-23 The Uab Research Foundation Saponin-based immunostimulants, pharmaceutical composition comprising said immunostimulants, therapeutic use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2851288B2 (ja) 1987-06-05 1999-01-27 アメリカ合衆国 癌診断および管理における自己分泌運動性因子
WO2013142142A1 (en) * 2012-03-23 2013-09-26 The Uab Research Foundation Natural saponin-based synthetic immunoadjuvants
WO2019183159A1 (en) * 2018-03-20 2019-09-26 The Uab Research Foundation Saponin-based vaccine adjuvants

Also Published As

Publication number Publication date
EP3941219A4 (en) 2022-12-21
KR20220004970A (ko) 2022-01-12
US20220152196A1 (en) 2022-05-19
JP2022525768A (ja) 2022-05-19
BR112021018555A2 (pt) 2021-11-30
CA3133985A1 (en) 2020-09-24
CN114126419A (zh) 2022-03-01
WO2020190959A1 (en) 2020-09-24
AU2020241955A1 (en) 2021-10-21
EP3941219A1 (en) 2022-01-26

Similar Documents

Publication Publication Date Title
MX2021011275A (es) Adyuvantes de vacunas a base de saponina.
WO2018089669A3 (en) Immunotherapeutic tumor treatment method
ECSP21000990A (es) Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2)
ZA202102696B (en) Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
EP3891291A4 (en) SYNTHESIS OF FUCOSYLATED OLIGOSACCHARIDE LNFP-V
MX2011012836A (es) Adyuvantes sinteticos de glucopiranosil-lipido.
MX2013005972A (es) Proceso para la preparacion de derivados de morfolinil antraciclina.
HN2012002555A (es) Activadores de guanilato ciclasa soluble
NO20064781L (no) Fremgangsmater og adjuvanser for a forbedre immunresponser mot vaksiner og fremgangsmater for anvendelse
EP3979810A4 (en) Microbiota-directed foods to repair a subject's gut microbiota
CA2763359C (en) New human rotavirus strains and vaccines
IN2014DN09791A (es)
MX2019004579A (es) Composiciones para el cuidado bucal y metodos de uso.
MX2020008842A (es) Sintesis a escala de proceso de urolitina a.
EP4234692A3 (en) Novel uses of a saponin and method for its isolation
WO2019212356A8 (en) Tetrazines for high click conjugation yield in vivo and high click release yield
ECSP044985A (es) Azitromicina de dosis única para infecciones respiratorias
NO20054349L (no) Kombinert terapi mot kreft omfattende nemorubicin med stralingsterapi
IN2012DN02816A (es)
NZ711238A (en) Compositions and methods for treating multi-drug resistant malaria
SG10201803158VA (en) Electromechanical transducer
MY160300A (en) Acylbenzene derivative
EP4335500A3 (en) Methods for the synthesis of deuterated dextromethorphan
MXPA05008906A (es) Estra-1,3,5-(10)-trien-3-il-sulfamatos 2-sustituidos, con actividad antitumoral.
WO2020190900A8 (en) Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof